Merck & Co’s shares have surged 78% over the past year to an all-time high of $153.53, pushing its market capitalization to $378.8 billion. The rally reflects investor confidence in the company’s drug pipeline, though valuation metrics suggest the stock is trading 7.5% above its fair value estimate of $142, according to Goldman Sachs’ models. Consensus targets imply a fair value near $150, with analyst upside currently pegged at -2.1%.
Analysts remain divided on Merck’s outlook. Goldman Sachs raised its price target to $160 from $140 while maintaining a Buy rating, citing potential upside from pipeline catalysts. UBS, however, downgraded the stock to Neutral with a $150 target, warning of valuation risks despite the company’s strong fundamentals.
Merck’s financial performance has strengthened in recent years, with revenue climbing from $48.7 billion in 2021 to an estimated $65.0 billion in 2025. Earnings per share rose from $5.14 to $7.28 over the same period, supported by a 77.2% gross margin and a 36.9% return on equity. However, revenue growth stalled at 1.3% in fiscal 2025, and the company’s forward price-to-earnings ratio stands at 55.2x, well above industry averages.
The company’s pipeline remains a key focus. The Phase 3 INTerpath-001 trial for Merck and Moderna’s mRNA melanoma treatment delivered the first positive Phase 3 results for an mRNA cancer therapy, offering a potential near-term catalyst. Other pipeline candidates include Sotatercept for pulmonary hypertension, CD388 for influenza (with peak U.S. sales potential of $8.4 billion), and HIV combination therapies. Strategic acquisitions have added over $20 billion in peak sales potential, while the patent extension for Keytruda to November 2029 provides additional revenue runway.
Despite the pipeline strength, technical indicators suggest caution. The stock’s daily Relative Strength Index (RSI) sits at 78.4, deep in overbought territory, while the Average Directional Index (ADX) signals strong trend momentum. A Dark Cloud Cover bearish candlestick pattern emerged on August 18, and support is seen in the $147–$148 range. The company’s low beta of 0.21 and high debt-to-equity ratio of 128.6% further underscore the valuation debate.
